Literature DB >> 7914704

Differential expression of autoreceptors in the ascending dopamine systems of the human brain.

J H Meador-Woodruff1, S P Damask, S J Watson.   

Abstract

The tone and regulation of the brain dopaminergic projections are, in part, determined by the presence or absence of dopamine (DA) autoreceptors: rate of DA synthesis and turnover, as well as both pattern and rate of neuronal firing, are modulated by the expression and activity of these autoreceptors. The expression of dopaminergic receptors in the midbrain DA cell groups, presumably reflecting DA autoreceptors, was determined in the brains of the rat, Old World monkey, and human. In the rat, both the substantia nigra (A9) and the ventral tegmental area (A10) appear to express DA autoreceptors. In the monkey and human, however, only the projections arising from the substantia nigra express these receptors; the limbic projections originating in the ventral tegmental area lack this substrate for DA autoregulation. These results indicate that in the human, the nigrostriatal and mesocorticolimbic dopamine systems may be differentially autoregulated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7914704      PMCID: PMC44593          DOI: 10.1073/pnas.91.17.8297

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  56 in total

Review 1.  Regulation of noradrenaline release by presynaptic receptor systems.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1977       Impact factor: 5.545

2.  Efferent connections of the substantia nigra and ventral tegmental area in the rat.

Authors:  R M Beckstead; V B Domesick; W J Nauta
Journal:  Brain Res       Date:  1979-10-19       Impact factor: 3.252

Review 3.  Relevance of dopamine autoreceptors for psychiatry: preclinical and clinical studies.

Authors:  H Y Meltzer
Journal:  Schizophr Bull       Date:  1980       Impact factor: 9.306

4.  Central catecholamine neuron systems: anatomy and physiology of the dopamine systems.

Authors:  R Y Moore; F E Bloom
Journal:  Annu Rev Neurosci       Date:  1978       Impact factor: 12.449

5.  Organization of the ascending striatal afferents in monkeys.

Authors:  J Szabo
Journal:  J Comp Neurol       Date:  1980-01-15       Impact factor: 3.215

6.  Efferent connections and nigral afferents of the nucleus accumbens septi in the rat.

Authors:  W J Nauta; G P Smith; R L Faull; V B Domesick
Journal:  Neuroscience       Date:  1978       Impact factor: 3.590

7.  The dopamine hypothesis of schizophrenia: focus on the dopamine receptor.

Authors:  S H Snyder
Journal:  Am J Psychiatry       Date:  1976-02       Impact factor: 18.112

8.  Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum.

Authors:  J H Fallon; R Y Moore
Journal:  J Comp Neurol       Date:  1978-08-01       Impact factor: 3.215

9.  Mesocortical dopamine neurons: rapid transmitter turnover compared to other brain catecholamine systems.

Authors:  M J Bannon; E B Bunney; R H Roth
Journal:  Brain Res       Date:  1981-08-10       Impact factor: 3.252

10.  Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons.

Authors:  L A Chiodo; B S Bunney
Journal:  J Neurosci       Date:  1983-08       Impact factor: 6.167

View more
  14 in total

1.  Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder.

Authors:  Robert E McCullumsmith; Lars V Kristiansen; Monica Beneyto; Elizabeth Scarr; Brian Dean; James H Meador-Woodruff
Journal:  Brain Res       Date:  2006-11-17       Impact factor: 3.252

2.  Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

Authors:  M E Stockton; K Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice.

Authors:  T E Koeltzow; M Xu; D C Cooper; X T Hu; S Tonegawa; M E Wolf; F J White
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

4.  Midbrain dopamine D2/3 receptor binding in schizophrenia.

Authors:  Heli Tuppurainen; Jyrki T Kuikka; Mikko P Laakso; Heimo Viinamäki; Minna Husso; Jari Tiihonen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-16       Impact factor: 5.270

5.  Nigral Stress-Induced Dopamine Release in Clinical High Risk and Antipsychotic-Naïve Schizophrenia.

Authors:  Huai-Hsuan Tseng; Jeremy J Watts; Michael Kiang; Ivonne Suridjan; Alan A Wilson; Sylvain Houle; Pablo M Rusjan; Romina Mizrahi
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

Review 6.  Cross-Species Alterations in Synaptic Dopamine Regulation After Chronic Alcohol Exposure.

Authors:  Cody A Siciliano; Anushree N Karkhanis; Katherine M Holleran; James R Melchior; Sara R Jones
Journal:  Handb Exp Pharmacol       Date:  2018

7.  Model-based parametric study of frontostriatal abnormalities in schizophrenia patients.

Authors:  Shoji Tanaka
Journal:  BMC Psychiatry       Date:  2010-02-27       Impact factor: 3.630

8.  Mechanisms explaining transitions between tonic and phasic firing in neuronal populations as predicted by a low dimensional firing rate model.

Authors:  Anca R Radulescu
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

9.  Interrelations between monoaminergic afferents and corticotropin-releasing factor-immunoreactive neurons in the rat central amygdaloid nucleus: ultrastructural evidence for dopaminergic control of amygdaloid stress systems.

Authors:  Marina Eliava; Deniz Yilmazer-Hanke; Esther Asan
Journal:  Histochem Cell Biol       Date:  2003-08-09       Impact factor: 4.304

Review 10.  Developmental changes in dopamine neurotransmission in adolescence: behavioral implications and issues in assessment.

Authors:  Dustin Wahlstrom; Paul Collins; Tonya White; Monica Luciana
Journal:  Brain Cogn       Date:  2009-11-26       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.